Drugs that contain Eribulin Mesylate

1. List of Halaven drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6214865 EISAI INC Macrocyclic analogs and methods of their use and preparation
Jul, 2023

(5 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6214865

(Pediatric)

EISAI INC Macrocyclic analogs and methods of their use and preparation
Jan, 2024

(11 months from now)

USRE46965 EISAI INC Intermediates for the preparation of analogs of Halichondrin B
Jan, 2027

(3 years from now)

USRE46965

(Pediatric)

EISAI INC Intermediates for the preparation of analogs of Halichondrin B
Jul, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 28, 2023
M Sep 13, 2025
Pediatric Exclusivity (PED) Mar 13, 2026

Market Authorisation Date: 15 November, 2010

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of HALAVEN before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in